OR WAIT null SECS
© 2021 MJH Life Sciences and Pharmaceutical Technology. All rights reserved.
© 2021 MJH Life Sciences™ and Pharmaceutical Technology. All rights reserved.
October 22, 2021
A new GMP facility in Raleigh, NC, and a starting materials facility in Paris, France, give Cellectis end-to-end, in-house manufacturing capacity for its UCART product candidates.
October 14, 2021
Avid Bioservices is building a viral vector development and manufacturing facility near its existing biologics manufacturing facility in California.
October 07, 2021
The $3 million investment will go towards various projects investigating key product attributes for therapeutic proteins.
September 14, 2021
Repligen and Navigo’s novel ligand could be the first to address antibody aggregation in low pH elution buffers.
AGC Biologics is expanding manufacturing capacity at its Heidelberg, Germany, facility for plasmid DNA and messenger RNA.
August 19, 2021
Corning’s new Ascent fixed bed reactor (FBR) system is an automated bioproduction platform designed to significantly improve yields and reduce bioproduction costs.
The collaboration will focus on the interactions between WTX-124 indukine and KEYTRUDA (pembrolizumab).
August 18, 2021
Artiva Biotherapeutics’s new R&D and GMP manufacturing center in San Diego, Calif., for NK cell therapies is expected to open in 2022.
August 13, 2021
Lykan Bioscience and Vineti will combine their capabilities to streamline process development and manufacturing to move cell therapies through clinical phases to commercialization.
August 12, 2021
Lonza and Sheba Medical Center have successfully dosed four patients with a CD19 autologous CAR-T cell therapy using Lonza’s Cocoon automated manufacturing platform.